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The receptor-mediated inhibition of intrinsic activities of GTP-binding proteins (G-proteins) was studied. Pertussis toxin (IAP)-substrate G-protein, 
GII, G~2 or G o, was prelabeled with [~t-a2p]GDP and reconstituted with synaptic membranes of the guinea pig cerebellum in the presence of 0.02~ 
of Chaps. Intrinsic activities of G-proteins were evaluated by the release of [~t-32p]GDP in exchange for added GppNHp or GDP in reconstituted 
preparations. U-50,488H (1 nM-10/~M), a specific x-subtype of opioid receptor agonist, inhibited the [~t-a2p]GDP release in exchange for added 
I/~M GppNHp in G~l-reconstituted preparations in a concentration-dependent ma ner. On the other hand, the x-opioid agonist at 10/~M increases 
the Km values of GppNHp, but not GDP in exchange for [~t-azp]GDP release in preparations reconstituted with G~I or G~2, but not with Go. These 
findings indicate that x-opioid receptor iscoupled to inhibition of intrinsic activities of G~l and G~2, but not G o, in guinea pig cerebellar membranes. 
In addition, it was revealed that the mode of action is mediated by a decrease in affinity of GTP (or its analog) for G-proteins, but not by a change 
in attinity of GDP. 
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1. INTRODUCTION 
The guanine nucleotide-binding regulatory proteins 
(G-proteins) are transducers communicating between 
receptors and effectors involved in the formation of in- 
tracellular second messengers. According to current 
models of signal transduction between receptors and G- 
proteins [1], the receptors, when stimulated by their 
agonists, enhance the exchange of GDP bound to 
coupled G-proteins for GTP. The activation of G- 
proteins is terminated by the hydrolysis of GTP to GDP 
(or Pi release) due to the low-Kra (high affinity) GTPase 
activity inherent in the G-protein a-subunits. Thus, the 
agonist-mediated increase in low-Kin GTPase activity is 
accepted as a secondary event o increase in GDP-GTP 
exchange [2,3]. 
However, in the course of studying the functional 
coupling between opioid receptors and G-proteins by 
measuring low-Km GTPase in synaptic membranes, we 
found an unexpected finding that an opioid agonist of 
x-subtype receptor inhibited this activity in guinea pig 
cerebellar membranes [4]. Further study reveals that the 
G-protein involved in such mechanisms i  pertussis tox- 
in (IAP)-sensitive [5]. The GTPase reaction proceeds on 
G-proteins as a result of sequential repetition of the two 
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processes, i.e. (i) the GDP-GTP exchange as a 'turn on' 
reaction in the signal transduction and (ii) the 
hydrolysis of GTP as a 'turn off' reaction. Therefore, 
it is an important question with regard to the 
physiological role in the signal transduction whether the 
x-receptor-mediated inhibition of low-Kin GTPase ac- 
tivity is attributed to the inhibition of 'turn on' reaction 
or to inhibition of 'turn off' one. 
The aims in the present study are to specify the kinds 
of IAP-substrate G-proteins relevant o, and to clarify 
the mode of action in, such inhibitory mechanisms of 
G-protein activities. 
2. MATERIALS AND METHODS 
2.1. Drugs 
U-50, 488H was a gift from Upjohn, Japan. [c~-32pIGTP was pur- 
chased from Dupont-New England Nuclear. 3-[(3-Cholamidopro- 
pyl)dimethylammonio]-l-propanesulfonate (Ch ps) was purchased 
from Dojindo Lab. (Kumamoto, Japan). Other reagents were of 
analytical grade and purchased from Sigma. 
2.2. Membrane preparation 
Male guinea pigs weighing 250-350 g were decapitated. The 
cerebellum was dissected out, homogenized in 10 vols of 0.32 M 
sucrose and centrifuged at 1000 x g for 10 rain. The supernatant was 
mixed with 9 vols of 20 mM Tris-HC1 buffer, pH 7.5 (buffer A), and 
centrifuged at 35 000 × g for 20 rain at 4°C. The pellet was 
resuspended in buffer A containing 1mM dithiothreitol (DTT) by use 
of Dounce-homogenizer to make a protein concentration of 0.5-0.8 
mg/ml. 
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2.3. Preparation of [ct-32p]GDP-bound G-proteins and measurement 
of [ct-32p]GDP release in exchange for GppNHp or GDP in 
reconstituted preparations 
Purified Gil, Gi2 or Go (50 pmol) derived from porcine brains [6] 
was incubated with [cz-32P]GTP (62.5 pmol) in 100 #l of buffer A con- 
taining 10 mM MgC12, 100 mM NaCl, I mM DTT, 1 mM EDTA and 
0.2°7o Chaps at 37°C for 60 min. The reaction mixture was applied on 
a Sephadex G-50 column (8 × 140 ram), which had been equilibrated 
in buffer A containing I mM DTT and 0.2070 Chaps, in order to 
remove free [c~-32P]GTP/GDP. The materials obtained at void 
volume were concentrated to 100 tzl (0.5 pmol/td) by use of Centricon 
30 (Amicon). Approximately 20070 of each G-protein was labeled with 
[c~-32p]GDP/GTP. The radioactive guanine nucleotide released from 
the labeled G-protein by incubation with 100 #M GTP-rS at 25°C for 
l0 min was analyzed with HPLC (Partisil 10 SAX, 25 cm × 4.6 ram, 
Whatman) system using a linear gradient (60 min) between water 
(Nano pure, Barnstead Co., Boston, MA) and 1.7 M ammonium for- 
mate (pH 3.7, adjusted with orthophosphoric a id), at a flow rate of 
1 ml/min. More than 95070 of radioactivity in any of the cases of Gil, 
Gi2 or Go was obtained at the retention time of GDP (22 rain), while 
less than 1070 at GTP (41 rain). 
In experiments for measurement of time-dependent release of 
[t~)zP]GDP, labeled G-protein (3 pmol) was incubated with 500 ttg 
protein of cerebellar membranes in 60 t*l of buffer A containing 1 mM 
DTT and 0.02°/0 Chaps at 4°C for 90 min. The reconstituted prepara- 
tion was incubated in the presence or absence of 10 #M 0-50, 488H 
in buffer A containing 100 mM NaC1, 6 mM MgCl2, 0.1 mM EDTA, 
1 mM DTT (buffer B) at 25°C. After 2 rain of incubation, 1 ttM 
GppNHp was then added to the reaction mixture and aliquots (100/zl) 
of mixture were successively removed and rapidly filtrated on GF/B 
filter (Whatman) for measurement of [et)zP]GDP release. The 
[~x)Ep]GDP release in exchange for GppNHp (or unlabeled GDP) 
was calculated from the difference between radioactivities retained on 
the GF/B filter at 0 and at each time. The number of counts retained 
on the filter at 0 min incubation represents he amounts of the labeled 
G-protein incorporated into membranes. Approximately 6007o of 
labeled G-protein (Gil, Gi2 or Go) was incorporated into membranes 
in the presence of 0.02070 Chaps. The incorporation was not changed 
between 0.01070 and 0.1070 Chaps. In order to normalize the 
[c~)2p]GDP release from different experiments, results were 
evaluated as the fractional release, as follows: fractional release (070) 
= 100 x [tx)2PIGDP release/[c~)2plGDP_labeled G-protein incor- 
porated into membranes. 
In experiments examining concentration-dependency of inhibitory 
effect of U-50, 488H on [~)2P]GDP release, 3rain of incubation time 
and l/~M GppNHp were adopted. In experiments esting concentra- 
tion-dependent release by GppNHp in the presence or absence of 10 
#M U-50, 488H, 3 min of incubation was adopted. In both experi- 
ments, 90/,l of reconstituted membranes (containing 0.3 pmol of G- 
protein and 50/~g protein of membranes) in buffer B in the presence 
or absence of U-50, 488H was incubated at 25°C for 2 rain, and then 
added by 10 #l of GppNHp or GDP. The incubation was terminated 
by adding 600 ttl of ice-cold buffer A and following by rapid filtration 
with GF/B. 
3. RESULTS 
In preparations of cerebellar membranes 
reconstituted with labeled Gil, there was a [tx)2p]GDP 
release in exchange for 1 tiM GppNHp, an 
unhydrolyzable analog of GTP, and the release increas- 
ed with the incubation time, while there was no signifi- 
cant release in the absence of the guanine nucleotide. 
When 10 #M U-50, 488H, a specific agonist at x- 
subtype of opioid receptor, was added 2 min prior to 
GppNHp addition, the release was inhibited (Fig. 1). 
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Fig. 1. Representative time-course profile of [c~)2p]GDP release in 
exchange for GppNHp in the presence or absence of the x-agonist in 
membranes reconstituted with labeled Gil. Results represent the frac- 
tional [a)2P]GDP release in exchange for 1 ttM GppNHp at each in- 
cubation time in the absence (©,A) or presence (O,B) of U-50, 488H 
at 10 tiM. The fractional release represents he ratio in radioactivity 
of [tx-J'P]GDP released at each indicated time to total one of labeled 
Gil incorporated into membranes (the amounts retained on the filter 
at 0 min incubation). (• )  the x-agonist-mediated inhibition obtained 
from A minus B. 
The inhibition reached a plateau at 2 min after the addi- 
tion of GppNHp and lasted for at least 7 min. 
In following experiments, the [cx)2p]GDP release at 
3 min after the addition of unlabeled guanine 
nucleotide (GppNHp or GDP) was used for analysis of 
x-agonist-induced inhibition. As shown in Fig. 2, the ~- 
agonist inhibited the [o~-32p]GDP release in exchange 
for 1 /zM GppNHp in preparations reconstituted with 
labeled Gil, in a concentration-dependent ma ner at a 
range from 1 nM to I0/~M. Similar inhibition was also 
observed with preparations reconstituted with Gi2, but 
not with Go. Table I shows effects of the x-agonist on 
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Fig. 2. Inhibition of [ct)2p]GDP release in exchange for GppNHp by 
various concentrations of U-50, 488H in membranes reconstituted 
with Gil. Results represent the U-50, 488H-induced inhibition of 
[~x)2p]GDP release, measured at 3 m in after the addition of 1 /~M 
GppNHp, as percentage of control (without ~t-agonist) fractional 
release. The control fractional release in this experiment was 
30070/3 min. 
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Table I
The x-agonist-induced inhibition of [a)2p]GDP release inexchange for GppNHp added in membranes r constituted with various kinds of labeled 
G-proteins 
n Control fractional release (070/3 min) a Maximal 070 inhibition of control release b ICso (nM) c 
Gil 6 27.6 ± 4.0 44.6 ± 14.4 d 1.4 ± 0.4 
Gi2 3 17.6 ± 1.2 36.4 ± 5.9 d 2.9 ± 0.9 
Go 5 24.9 ± 1.l 0 > 1000 
a The fractional release at 3 min after addition of 1 #M GppNHp. The release in Gi2-preparations was significantly ower than that in G~I or Go 
(P< 0.05), while there was no significant change between Gil or Go (Student's t-test) 
b The 070 inhibition of control fractional release by l0/~M U-50, 488H 
¢ The concentration f U-50, 488H required for half-maximal inhibition of control fractional release at 3 min after the addition of I #M GppNHp. 
There was no significant change between Gil- and Gi2-preparations 
d The x-agonist-mediated inhibition of [a-32p]GDP release was significant (P< 0.05, paired t-test) 
[oL-32p]GDP release from these labeled G-proteins. The 
control fractional release in exchange for added 
GppNHp from Gi2 was significantly smaller than that 
from Gil or Go. These findings uggest that the intrinsic 
GDP-GTP exchange activity in Gi2 is lower than those 
in the other two G-proteins. The ICso of U-50, 488H in 
Gil was 2-fold lower than that in G~2, but the difference 
was not statistically significant. 
The [o~-32p]GDP release from Gil-preparations in- 
creased with concentrations of GppNHp in control 
(Fig. 3A, open circle). The Km and maximal release 
were calculated to be 0.20 _+ 0.08 ~M and 35.4 _+ 
4.8%/3 min, respectively, from double reciprocal plot 
analysis (Table II). When U-50, 488H at 10/tM was 
added, the release was significantly inhibited in various 
concentrations of GppNHp (Fig. 3A, closed circle). 
From the kinetic analysis, it was revealed that the Km 
was increased approximately 3-fold, while there was no 
significant change in maximal release. Similar 
[ct-a2p]GDP release was also observed with the addition 
of various concentrations of unlabeled GDP, while 
there was no inhibition by U-50, 488H at 10/zM (Fig. 
3B). 
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Fig. 3. Effects of the x-agonist on the [~)2p]GDP release in exchange 
for GppNHp or GDP in membranes reconstituted with Gil. Results 
represent the effects of U-50, 488H at 10/~M on fractional release for 
3 rain in exchange for various concentrations of guanine nucleotide, 
GppNHp (A) or GDP (B). Data represent the mean ± SE from 6 
separate experiments. *P<0.05, **P<0.01 (paired t-test), compared 
to control (without U-50, 488H). Other details are given in the legend 
of Fig. I. 
As shown in Table II, in preparations reconstituted 
with Gi2, [a)2p]GDP was also released in exchange for 
added GppNHp or unlabeled GDP in control, and the 
x-agonist selectively increased the Km value of 
GppNHp, but not the maximal fractional release. 
However, U-50, 488H showed no significant change in 
the release in exchange for GppNHp or unlabeled GDP. 
4. DISCUSSION 
Reconstitution experiments are a well accepted means 
to clarify the molecular basis of coupling between 
receptors and G-proteins. Previously we have reported 
that the functional reconstitution experiments using 
purified G-protein and receptors in membranes 
pretreated with IAP or N-ethylmaleimide (NEM), both 
known to inactivate G-proteins, such as Gil, Gi2 and Go 
by ADP-ribosylation or alkylation of their ot-subunits 
[7,8]. In these previous studies, the inactivation of 
naturally occurring G-proteins with IAP or NEM is 
definitely required, in order to eliminate the contribu- 
tion of unspecified G-proteins naturally occurring in 
membranes. However, there is some risk of receptors 
coupling to G-proteins devoid of physiological relevan- 
cy when only one kind of G-protein is reconstituted in 
the assay system after inactivation of G-proteins by 
lAP or NEM, as the primary structures of IAP- 
substrate G-proteins, Gil, Gi2 and Go are very similar 
to each other [9]. The present study is sharply in con- 
trast with such reports in that membrane preparations 
were used without any pretreatment. Such membrane 
preparations without inactivation of naturally occur- 
ring G-proteins therein (Gil, Gi2 and Go) seem to have 
an advantage in detecting selective coupling between 
membrane-bound receptors and labeled G-proteins 
with [c~-3zP]GDP, since the [a)zP]GDP release in ex- 
change for unlabeled guanine nucleotide, is definitely 
from the reconstituted G-protein. 
Labeled G-proteins are easily incorporated into mem- 
branes simply by incubation at 4°C for 90 min in the 
presence of Chaps, a detergent, atconcentrations more 
than 0.01%. The incorporation of G-proteins in mem- 
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Table I1 
Kinetic analysis of the x-agonist-mediated inhibition of [a-3zP]GDP release inexchange for GppNHp or GDP in membranes r constituted with 
various kinds of labeled G-proteins 
Km OxM) Maximal fractional release (%/3min) 
GppNHp GDP GppNHp GDP 
Gil 
control 0.20 ± 0.08 0.24 ± 0.04 35.4 ± 4.8 27.0 _+ 2.1 
U-50, 488H a 0.58 +_ 0.14 b 0.27 ± 0.09 29.9 ± 5.2 28.1 ± 2.0 
G~2 
control 0.45 ± 0.15 0.14 ± 0.03 31.1 ± 5.5 24.7 ± 1.7 
U-50, 488H a 1.26 ± 0.24 b 0.17 ± 0.05 27.9 ± 2.2 24.7 ± 1.1 
Go 
control 0.22 + 0.03 0.34 + 0.15 32.8 ± 1.0 29.7 ± 1.6 
U-50, 488H a 0.26 ± 0.07 0.34 ± 0.12 30.7 ± 1.2 33.7 ± 3.5 
Results represent the Km and maximal fractional release (%/3 min) calculated from double reciprocal plot analysis from at least 6 separate x- 
periments. 
a The concentration was 10/~M 
b The difference is statistically significant (P< 0.05, paired t-test), compared to each control. Other details are given in the legend of Fig. 1 
branes was approximately 60°70 when Chaps was used in 
concentrations between 0.01 070 and 0.1 070. On the other 
hand, a selective x-agonist, U-50, 488H, produced no 
significant change in [ct-32p]GDP release in prepara- 
tions with Gil or Gi2, when the concentration f Chaps 
was more than 0.04070 (unpublished data). It is likely 
that various kinds of membrane proteins are partially 
solubilized in the presence of higher concentrations of 
detergent and interfere the functional coupling between 
receptors and G-proteins. Accordingly, we chose 0.02070 
of Chaps for incorporation of G-proteins into mem- 
branes. 
In the present study, we provided irect evidence of 
receptor-coupled inhibition of intrinsic (GDP-GTP ex- 
change) activity of G-protein ('turn on' reaction). 
However, we have not yet obtained ata about the x- 
receptor-mediated changes in GTPase activity per se 
('turn off' reaction). Taking into account that most of 
G-protein-coupled receptors mediate the stimulation of 
the intrinsic activities of G-protein [1-3], the present 
finding may be the first evidence for receptor-mediated 
inhibition of G-protein activity in signal transduction 
mechanisms through plasma membranes. Experimental 
support for this conclusion is as follows. First, the 
agonist-induced inhibition of [a-32p]GDP release in ex- 
change for GppNHp was observed when membranes 
were reconstituted with labeled Gil or Gi2, but not with 
Go. Second, the mode of inhibition is related to the 
decrease in affinity for GppNHp (as a GTP analog) in 
GDP-GTP exchange r action, but not to the increase in 
affinity for GDP. 
The Gil or Gi2 inhibited via x-opioid receptors will 
lead to inhibition of certain effector system(s) inthe cell 
membrane. Here, adenylate cyclase is an unlikely can- 
didate, since we obtained no significant changes to it by 
the x-agonist in cerebeUar membranes of the guinea pig 
(unpublished ata). The lack of effect on adenylate 
cyclase by the x-agonist was supported by other in- 
vestigators [10]. However, the possibility remains that 
x-agonist blocks the inhibition of adenylate cyclase 
mediated through activation of Gil or Gi2 by other 
receptors. Phospholipase C seems to be a more likely 
candidate. There are some reports that IAP-sensitive in- 
hibition of phospholipase C via stimulation of 
dopamine D2- or adenosine Al-receptors was observed 
[11]. We also have data that the x-opioid agonist in- 
hibits GTP-stimulated phospholipase C activity [12], in 
an IAP-sensitive manner [13]. Thus, it is plausible that 
the inhibitory regulation of Gi (Gil and/or Gi2) activity 
by receptor stimulations leads to inhibition of 
phospholipase C activity, respectively. 
The present communication may be the first to report 
the direct demonstration f receptor-mediated inhibi- 
tion of G-protein activity in cell membranes; intrinsic 
Gil or Gi2 activity was inactivated via opioid receptors 
of the x-subtype in the guinea pig cerebellum. 
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